ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · J Rheumatol · 2026-11-01

Secondary analysis of four phase III trials and open-label extensions in axSpA (n=586) and PsA (n=1112): with bimekizumab, mean EQ VAS improved 20.2–21.3 (axSpA) and 17.1–17.3 points (PsA) by year 3; most had meaningful work-impairment improvement. Observed cases, no comparator.

Secondary analysisn = 1,698
Nikiphorou et al. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis
Rheumatology · RMD Open · 2026-05-13

Pooled open-label extension of 2 bimekizumab trials in axial spondyloarthritis: of 494 entering the extension, 425 completed week 164, with mean improvements from baseline in spinal pain (−4.3), BASFI (−2.9), fatigue and SF-36 PCS (+12.3); no comparator.

RCTn = 586
Navarro-Compán et al. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension
Rheumatology · RMD Open · 2026-03-10

Pooled safety analysis of six phase IIb/III studies of bimekizumab 160 mg every 4 weeks in 848 patients with axSpA and 1409 with PsA: adverse events 129.6 and 126.9 per 100 patient-years, oral candidiasis 3.5 and 3.8; no active tuberculosis and no new safety signals.

RCTn = 2,257 patients
Mease et al. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Rheumatology · RMD Open · 2025-11-28

In 2-year data from two phase 3 trials and their open-label extension in axial spondyloarthritis (586 patients; 456 completed week 104), bimekizumab-treated patients reported sustained falls from baseline in spinal pain (−4.3), morning stiffness (−4.3) and BASFI (−2.9).

RCTn = 586
Marzo-Ortega et al. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
Dermatology · J Am Acad Dermatol · 2025-11-15

Pooled analysis of two phase 3 RCTs and their open-label extension in moderate to severe hidradenitis suppurativa (556 patients entered): bimekizumab adverse event rates did not rise in Year 2 (235.7 vs 261.6/100 PY); 85.4% achieved HiSCR50 at Year 2.

Secondary analysisn = 556
Sayed et al. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.